Oncolytic adenovirus
AssigneeOnyx Pharmaceuticals, Inc.
InventorsLeisa Johnson, Ali Fattaey, Terry Hermiston
Life of this patent
Estimating the term…
Abstract
Viral vectors and methods of making such vectors are described that preferentially kill neoplastic but not normal cells, the preferred vector being an adenovirus that has the endogenous promoters in the E1A and/or E4 regions substituted with a tumor specific promoter which is preferably E2F responsive.
Claims11
An adenoviral vector comprising E2F binding sites that control the expression of an early adenoviral gene, and a mutation in the E1a region of said adenoviral vector, which mutation causes a loss of RB binding to the protein encoded by the E1a region.
An adenoviral vector comprising a viral transcriptional nucleotide regulatory site that controls the expression of an early adenoviral gene, wherein said site is inactivated by the insertion of E2F binding sites such that said E2F binding sites control the expression of said adenoviral gene, and said adenoviral vector further comprises a mutation in the E1a region of, which mutation causes a loss of RB binding to the protein encoded by the E1a region.
Dependencies are inferred from the claim text.